Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis

Hitoshi Terui; Rintaro Moroi; Atsushi Masamune; Setsuya Aiba; Kenshi Yamasaki

doi:10.1159/000529080

Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis

Hitoshi Terui, Rintaro Moroi, Atsushi Masamune, Setsuya Aiba, Kenshi Yamasaki

Research output: Contribution to journal › Article › peer-review

Abstract

Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy.

Original language	English
Pages (from-to)	22-25
Number of pages	4
Journal	Case Reports in Dermatology
DOIs	https://doi.org/10.1159/000529080
Publication status	Accepted/In press - 2023
Externally published	Yes

Keywords

?4?7 integrin
Palmoplantar pustulosis
Vedolizumab

ASJC Scopus subject areas

Dermatology

Access to Document

10.1159/000529080

Cite this

@article{ceb1fbfac6044b199933953dd86b5e23,

title = "Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis",

abstract = "Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy.",

keywords = "?4?7 integrin, Palmoplantar pustulosis, Vedolizumab",

author = "Hitoshi Terui and Rintaro Moroi and Atsushi Masamune and Setsuya Aiba and Kenshi Yamasaki",

year = "2023",

doi = "10.1159/000529080",

language = "English",

pages = "22--25",

journal = "Case Reports in Dermatology",

issn = "1662-6567",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis

AU - Terui, Hitoshi

AU - Moroi, Rintaro

AU - Masamune, Atsushi

AU - Aiba, Setsuya

AU - Yamasaki, Kenshi

PY - 2023

Y1 - 2023

N2 - Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy.

AB - Palmoplantar pustulosis (PPP) is a chronic skin inflammatory disease in which blisters and pustules repeatedly develop on palms and soles. PPP is often refractory to topical therapy, oral therapy, phototherapy, and biologics that are usually applied for PPP. We report a patient with PPP improved by vedolizumab (anti-α4β7 integrin antibody) treatment for ulcerative colitis, suggesting the possibility of a new molecular target for PPP therapy.

KW - ?4?7 integrin

KW - Palmoplantar pustulosis

KW - Vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85147508304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147508304&partnerID=8YFLogxK

U2 - 10.1159/000529080

DO - 10.1159/000529080

M3 - Article

AN - SCOPUS:85147508304

SN - 1662-6567

SP - 22

EP - 25

JO - Case Reports in Dermatology

JF - Case Reports in Dermatology

ER -

Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this